Clinical trial
Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of…
NCT00357773 · Laboratoires Thea, Industry · Completed
Key facts
| NCT number | NCT00357773 |
|---|---|
| Title | Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis |
| Official title | Clinical Efficacy and Safety of T1225 1.5% Eye Drops (3-Day Treatment) Versus Tobramycin 0.3 % Eye Drops (7-Day Treatment) in the Treatment of Purulent Bacterial Conjunctivitis |
| Lead sponsor | Laboratoires Thea, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Conjunctivitis, Bacterial |
| Intervention type | Drug |
| Interventions | Azithromycin (T1225) |
| Start date | May 1, 2004 |
| Completion | Jun 1, 2005 |
| First posted | Jul 27, 2006 |
| Last update posted | Jul 27, 2006 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: